To become a leading company in the research and application of safe & effective probiotics technology in Vietnam & Southeast Asia.
Prioritizing human health care, HURO BIOTECH invests in research and application of modern biotechnology innovations into products serving public health; ensuring the pricing level is really suitable to the economy of Vietnamese people and middle-income countries.
The background of serious and dedicated scientific research comes from a team of world-leading microbiology experts. The products are the result of persistent scientific research and proven safety - effectiveness. Each product is a specialized scientific solution for each object and is suitable for economic conditions.
After more than 25 years of dedicated research, a leading professor of microbiology technology – Simon Cutting – Doctor of Microbiology at Oxford University (UK) – Lecturer at Royal Holloway (UK) has isolated beneficial strains of the bacterium with “strong viability” is Bacillus subtilis HU58.
This probiotic is in the form of a spore – the spore coat is like an armor around the good bacteria to help them survive in the extremely low acidic pH of the stomach or the alkaline pH of the small intestine; resistant to temperatures up to 95ºC and has high adhesion to the intestinal mucosa. Because of the above properties, this strain of beneficial bacteria is preserved in almost absolute numbers when it reaches the small intestine – a favorable environment for them to start germinating into vegetative cells and take effect.
Bacillus subtilis HU58 has mechanisms to balance intestinal microflora such as Competition for nutrients, energy, and secretion of Bacteriocin to destroy harmful microorganisms.
Moreover, this is a probiotic strain capable of producing 3 main groups of digestive enzymes to digest food and enhance the absorption of nutrients including alpha – Amylase (an enzyme that hydrolyzes starch), Lipase (an enzyme that hydrolyzes fats), and Protease (an enzyme that hydrolyzes protein).
Within the framework of an international research collaboration project funded & strictly controlled by the UK Government; the biologically active ingredient SPOR-COV® has been shown to be effective in the prevention and relief of symptoms of various types of upper respiratory tract viruses and persistent symptoms such as Influenza A Virus or even SAR- COV-2.
The biologically active ingredient SPOR-COV® has created from the beneficial bacteria Bacillus subtilis DSM 32444K spores with heat inactivation treatment to provide natural immune-boosting support in the upper respiratory tract. Mechanisms include Toll-like receptor stimulation, cytokines induction, and increased IGA antibodies.
SPOR-COV® was studied for safety by Charles River Laboratories and was found to be non-toxic and safe for human use. Several trials evaluating the efficacy of SPOR-COV® against influenza viruses were conducted at the University of Liverpool (UK).
Recently, a study evaluating the effectiveness of reducing symptoms of influenza A (H7N9) virus infection was published in the journal Vaccines with the participation of scientists from the UK: Department of Biological Sciences – Royal Holloway University, SporeGen Biotechnology Company, Destiny Pharma Pharmaceutical Company and Huro Biotech (Vietnam).
